SEC Filings
Ocugen Delays Vote Again On Adding 250 Million Authorized Shares
The board backs the proposal unanimously, while broker-held shareholders face a warning about relying on earlier voting instructions.
OCGN
Ocugen (OCGN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Ocugen Says September Stargardt Panel Review Was No Efficacy Test, And Baselines Will Balance By Month 12
The chief medical officer says the 63-patient trial is powered at close to 90%, with topline data due in the second quarter of 2027.
Earnings
Ocugen's Quarterly Loss Shrinks To $3.6 Million On A Derivative Gain, Not Core Results
A $16.6 million non-cash gain cut the net loss from $20.1 million, while first Phase 3 data for OCU400 are expected in early 2027.
SEC Filings
Ocugen Says Bahamas Regulator Gave Provisional Approval To OCU400 Early Access Program
Full approval and patient dosing are expected within 90 days, and Ocugen cites potential revenue of $1-2M per patient.
SEC Filings
Ocugen Gives Roots Pharmaceutical Middle East Rights To OCU400 For Up To $255 Million In Sales Milestones
Ocugen would also collect a 22% royalty on net sales and manufacture the gene therapy under a separate supply agreement.
SEC Filings
Ocugen Pushes Vote On 250 Million More Authorized Shares To October 26
The special meeting was adjourned a second time, with the July 27 record date unchanged.